Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1987-04-01
To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals
who had survived one episode of out-of-hospital cardiac arrest.
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
Completed
University of Washington
Phase 3
1987-04-01
To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals
who had survived one episode of out-of-hospital cardiac arrest.
Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1985-07-01
To determine whether electrophysiologic study (EPS) or Holter monitoring (HM) was the better
method for selecting effective long-term antiarrhythmic drug therapy in patients with
sustained ventricular tachycardia, ventricular fibrillation, or an episode of aborted sudden
death.
Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)
Completed
University of Utah
Phase 3
1985-07-01
To determine whether electrophysiologic study (EPS) or Holter monitoring (HM) was the better
method for selecting effective long-term antiarrhythmic drug therapy in patients with
sustained ventricular tachycardia, ventricular fibrillation, or an episode of aborted sudden
death.
Antiarrhythmics Versus Implantable Defibrillators (AVID)
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1992-09-01
To evaluate if use of an implantable cardiac defibrillator (ICD) results in reduction in
total mortality, when compared with conventional pharmacological therapy, in patients
resuscitated from sudden cardiac death who are otherwise at very high risk of mortality from
arrhythmic causes.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
